Interleukin-17A mediates tobacco smoke-induced lung cancer epithelial-mesenchymal transition through transcriptional regulation of Delta Np63 alpha on miR-19
Interleukin-17A mediates tobacco smoke-induced lung cancer epithelial-mesenchymal transition through transcriptional regulation of Delta Np63 alpha on miR-19
复制标题
Interleukin-17A 通过 miR-19 上 Delta Np63 α 的转录调节介导烟草烟雾诱导的肺癌上皮间质转化
DOI:
10.1007/s10565-021-09594-0
复制
发表时间:
2021
影响因子:
6.1
通讯作者:
Zhong Caiyun
中科院分区:
文献类型:
--
作者:
Xie Chunfeng;Zhu Jianyun;Huang Cong;Yang Xue;Wang Xiaoqian;Meng Yu;Geng Shanshan;Wu Jieshu;Shen Hongbin;Hu Zhibin;Meng Zili;Li Xiaoting;Zhong Caiyun
Interleukin-17A (IL-17A) is an essential inflammatory cytokine in the progress of carcinogenesis. Tobacco smoke (TS) is a major risk factor of lung cancer that influences epithelial-mesenchymal transition (EMT) process. However, the potential mechanism by which IL-17A mediates the progression of lung cancer in TS-induced EMT remains elusive. In the present study, it was revealed that the IL-17A level was elevated in lung cancer tissues, especially in tumor tissues of cases with experience of smoking, and a higher IL-17A level was correlated with induction of EMT in those specimens. Moreover, the expression of ΔNp63α was increased in IL-17A-stimulated lung cancer cells. ΔNp63α functioned as a key oncogene that bound to the miR-17-92 cluster promoter and transcriptionally increased the expression of miR-19 in lung cancer cells. Overexpression of miR-19 promoted EMT in lung cancer with downregulation of E-cadherin and upregulation of N-cadherin, while its inhibition suppressed EMT. Finally, the upregulated levels of IL-17A, ΔNp63α, and miR-19 along with the alteration of EMT-associated biomarkers were found in lung tissues of TS-exposed mice. Taken together, the abovementioned results suggest that IL-17A increases ΔNp63α expression, transcriptionally elevates miR-19 expression, and promotes TS-induced EMT in lung cancer. These findings may provide a new insight for the identification of therapeutic targets for lung cancer.Graphical abstract